Daily subcutaneous liraglutide 3.0 mg, alongside lifestyle therapy, reduces body weight by around 8% in adults with obesity, which can increase to 11.515.7% with added intensive behavior therapy, exercise, and caloric restriction (Table 2)
Microdosing GLP-1 or GLP-1/GIP is an off-label longevity product and not a dedicated weight management solution
However, rats exhibited a non-significant tendency to decrease performance in Q1 from 12:00 to 18:00 relative to the other quartiles
At the high end (20 units): 2 mg per injection
Rather than operating through a single pathway, the peptide influences multiple cellular systems that converge on tissue repair and regeneration
Most long-term protocols settle at 12 mg per day because the doseresponse curve plateaus